Cargando…
SAT-272 A Phase 2 Comparison of a Stable Liquid Glucagon to Placebo for the Treatment of Congenital Hyperinsulinism
OBJECTIVE: A novel ready-to-use stable liquid Glucagon (CSIG; Xeris Pharmaceuticals) delivered continuously through a patch pump, was evaluated for the treatment of congenital hyperinsulinism (CHI). METHOD: This was a Phase 2, randomized, placebo-controlled, double-blind trial with open-la...
Autores principales: | Thornton, Paul, Cummins, Martin, Junaidi, Khaled, Johnson, Kenneth |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Endocrine Society
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6552081/ http://dx.doi.org/10.1210/js.2019-SAT-272 |
Ejemplares similares
-
Efficacy of Dose-Titrated Glucagon Infusions in the Management of Congenital Hyperinsulinism: A Case Series
por: Salomon-Estebanez, Maria, et al.
Publicado: (2020) -
Successful Use of Intragastric Dextrose in a Unique Presentation of Congenital Hyperinsulinism
por: Gurnurkar, Shilpa, et al.
Publicado: (2021) -
Corrigendum: Efficacy of Dose-Titrated Glucagon Infusions in the Management of Congenital Hyperinsulinism: A Case Series
por: Salomon-Estebanez, Maria, et al.
Publicado: (2020) -
MON-080 Unusual Association Between Congenital Hyperinsulinism and Neurofibromatosis Type 1
por: Marinescu, Andreea S, et al.
Publicado: (2020) -
Global Registries in Congenital Hyperinsulinism
por: Pasquini, Tai L. S., et al.
Publicado: (2022)